secondary hypertension
Think of it with resistant hypertension, hypokalaemia, an adrenal nodule, onset at a young age or sudden worsening, an abdominal bruit, AKI after starting RASi, or severe/malignant hypertension. Primary aldosteronism is the commonest treatable cause. Endocrine Society 2025 says screen everyone with hypertension (ARR). HTN Canada 2020 says screen only targeted groups. Phaeo: plasma free or urine fractionated metanephrines → α-blockade before any β-blocker.
who to work up
HTN Canada 2025 referral triggers: unexplained sudden worsening, hypokalaemia, adrenal nodule, abdominal bruit, AKI after starting antihypertensives, severe or malignant hypertension, hypertension at a young age, resistant hypertension.
primary aldosteronism — ES 2025 vs HTN Canada 2020
| Endocrine Society 2025 | Hypertension Canada 2020 | |
|---|---|---|
| who to screen | all adults with hypertension (2, low certainty; feasibility-dependent). Rescreen if hypertension worsens or becomes resistant, new hypokalaemia, or AF without structural heart disease | targeted: spontaneous K⁺ <3.5 or diuretic-induced K⁺ <3.0; resistant to ≥3 drugs; incidental adrenal adenoma |
| screening test | morning, seated: aldosterone + renin (PRA or DRC) → ARR; measure K⁺ alongside (low K⁺ lowers aldosterone → false negative); don’t restrict sodium | morning, ambulatory ≥2 h then seated 5–15 min; correct K⁺, liberalise sodium |
| drug prep | either test on current drugs and interpret, or minimal withdrawal: stop MRA/ENaC inhibitors 4 wk (they raise renin → false-negative screen); β-blockers/central α₂-agonists 2 wk. Full withdrawal adds diuretics (4 wk) and ACEi/ARB/DHP CCB/SGLT2i (2 wk) | stop MRA, K⁺-sparing and K⁺-wasting diuretics 4–6 wk. If non-diagnostic, stop β-blockers, central α₂-agonists, ACEi, ARB, DRI, DHP CCB for 2 wk |
| bridging drugs | hydralazine (+ verapamil SR), α₁-blockers, non-DHP CCB, moxonidine | slow-release verapamil, diltiazem, hydralazine, prazosin, doxazosin, terazosin |
| positive screen | suppressed renin (PRA ≤1 ng/mL/h or DRC ≤8.2 mU/L) + aldosterone ≥277 pmol/L (immunoassay) [≥208 LC-MS/MS] + ARR >70 pmol/L per mU/L (or >555 pmol/L per ng/mL/h); local cut-offs preferred | ARR (pmol/L per ng/mL/h) >555 (sensitive) or >750 (specific); per DRC mIU/L >60 / >91 |
| confirmation | aldosterone suppression test only if intermediate probability of lateralising PA and the patient wants surgery. Skip it if renin undetectable + aldosterone >554 pmol/L (immunoassay) with hypokalaemia or resistant hypertension, or if not a surgical candidate → start MRA | always: ≥1 of IV saline (2 L/4 h; PA if aldo >280 pmol/L, unlikely <140), oral salt load (24-h urine aldo >33 nmol/day), ARR >1400 with aldo >440 pmol/L, or captopril test |
| subtyping | after biochemical confirmation (incidentalomas common): CT + adrenal vein sampling before choosing surgery vs medical therapy. AVS can be skipped if age <35, marked PA, hypokalaemia and >1 cm unilateral adenoma | CT/MRI, then AVS before unilateral adrenalectomy (an adrenal nodule may be non-functional) |
| also | 1-mg overnight dexamethasone test in every PA with adenoma (cortisol >50 nmol/L = autonomous cortisol secretion) | genetic testing for GRA if FHx of PA or stroke ≤40 y, or onset ≤20 y with negative imaging |
| treatment | lateralising + surgical candidate → laparoscopic unilateral adrenalectomy. Otherwise lifelong MRA: spironolactone preferred (cost) over other MRAs, MRA over amiloride/triamterene. Titrate up to raise renin if BP uncontrolled | unilateral → adrenalectomy; bilateral or non-surgical → MRA (spironolactone low–moderate dose) |
- ACC/AHA 2025 sits between the two: screen resistant hypertension (with or without hypokalaemia), any hypokalaemia (spontaneous or diuretic-induced), OSA, adrenal incidentaloma, family history of early-onset hypertension or stroke <40 y; consider in all stage 2 (≥140/90). Screen on current drugs, stopping only MRAs
- ES 2025 repeat rules: negative screen with hypokalaemia → correct K⁺ and repeat; moderate–high pretest probability or suppressed renin with aldosterone 138–277 pmol/L → repeat on another day. On a β-blocker, aldosterone 277–416 pmol/L may be a false positive; above that, PA likely
- ES 2025 renin cut-off: DRC ≤8.2 mU/L (the original Figure 1 printed mU/mL; corrected August 2025)
- ES 2025: genetic screening for all first-degree relatives in familial hyperaldosteronism and for PA onset <20 y. Spironolactone default doesn’t apply if hyperkalaemia, advanced CKD or pregnancy; gynaecomastia → eplerenone (or amiloride)
- MRA dosing (ES 2025): spironolactone 12.5–25 mg/day or eplerenone 25 mg daily–BID to start; 50 mg/day spironolactone if severe hypokalaemia. Check K⁺, Cr and renin within 2–3 months; adjust doses every 8–12 weeks
- After treatment (surgery or MRA), eGFR often falls and Cr rises: removing the glomerular hyperfiltration unmasks underlying CKD → monitor renal function
- CKD lowers renin and can raise aldosterone → more false-positive screens
False positive (renin lowered): β-blockers, clonidine, methyldopa, NSAIDs, and oestrogen-containing OCP/HRT when renin is measured as DRC. False negative (renin raised): MRA, ENaC inhibitors, diuretics, ACEi/ARB, SGLT2i, and drospirenone (an MRA). Hypokalaemia → falsely low aldosterone. HTN Canada 2020: stop the OCP for 1 month, or measure PRA instead of DRC.
- HTN Canada 2020: ARR >1400 + aldosterone >440 pmol/L confirms PA (no suppression test needed)
- ES 2025: suppressed renin is required — high ARR with unsuppressed renin is not PA
renovascular hypertension — HTN Canada 2020
atherosclerotic renal artery stenosis
- Investigate if ≥2 of: onset or worsening at age >55 or <30; abdominal bruit; resistant to ≥3 drugs; Cr rise ≥30% on ACEi/ARB; other atherosclerotic disease; recurrent flash pulmonary oedema with BP surges
- Screening tests: Doppler US, CTA, MRA (eGFR >30), captopril renal scan (eGFR >60). eGFR <30 → choose case by case with nephrology; avoid gadolinium MRA first
- Medical therapy first: stenting adds nothing over optimal medical therapy (Grade B)
- Angioplasty ± stent only for: hypertension resistant to maximal therapy, progressive renal function loss, or acute pulmonary oedema
fibromuscular dysplasia
- Investigate if ≥1 of: unexplained kidney size asymmetry >1.5 cm, bruit without atherosclerosis, FMD elsewhere, family history of FMD
- Screen with CTA or MRA (similar accuracy)
- Confirmed → screen cervicocephalic arteries and for intracranial aneurysm; refer to a hypertension specialist
- Angioplasty without stenting (stent only for periprocedural dissection)
phaeochromocytoma and paraganglioma
For full biochemical, imaging, genetic, and surgical detail, see phaeochromocytoma and paraganglioma.
who to test (HTN Canada 2020)
Paroxysmal/labile or severe (≥180/110) refractory hypertension; spells (headache, palpitations, sweating, pallor); hypertension triggered by β-blockers, MAOIs, micturition, surgery or anaesthesia; adrenal incidentaloma; hereditary syndromes (MEN2, NF1, VHL).
biochemistry
- Plasma free metanephrines or urine fractionated metanephrines (ES 2014, strong rec). HTN Canada 2020 lists 24-h urine first with plasma “where available”. Never VMA
- Plasma sample drawn supine, compared against supine reference ranges
- ≥3× upper limit, or both normetanephrine and metanephrine raised → rarely false positive → image
- Borderline → repeat supine. Still raised → clonidine suppression test
- False positives: TCAs, SNRIs, MAOIs, sympathomimetics, D2 antagonists (metoclopramide, antipsychotics), acetaminophen (LC-ECD assays), critical illness
- Image only after biochemical confirmation. ES 2014 prefers CT first. HTN Canada 2020 prefers MRI. MRI for skull base/neck, metastatic disease, or pregnancy
- Offer genetic testing to all (shared decision). SDH testing for paraganglioma, SDHB if metastatic
pre-operative blockade
- All functional tumours need pre-op blockade (ES 1); α-blocker first choice (2) (phenoxybenzamine, doxazosin or prazosin) for 7–14 days to normalise BP and HR (ES 2014). HTN Canada 2020 says 10–14 days
- High-sodium diet + fluids → reverses volume contraction, prevents post-resection hypotension
- β-blocker only after adequate α-blockade, for tachycardia. Avoid diuretics
- Monitor BP, HR and glucose in the immediate post-op period (1)
- Laparoscopic adrenalectomy for most; open if large (>6 cm) or invasive. Lifelong annual metanephrines
Unopposed α-stimulation → hypertensive crisis. Labetalol is no substitute: fixed α:β ≈ 1:5, so it can cause paradoxical hypertension. Don’t use it as initial therapy.
Prepared 2026-11-01. Not yet verified — check every number against the sources.